CN Stock MarketDetailed Quotes
301333 R&G PharmaStudies
- 55.58
- -3.45-5.84%
Noon Break Nov 18 11:30 CST
5.37BMarket Cap44.32P/E (TTM)
58.90High54.87Low15.06KlotVolume58.42Open59.03Pre Close84.48MTurnover2.63%Turnover Ratio33.02P/E (Static)96.58MShares73.0852wk High2.98P/B3.19BFloat Cap33.0552wk Low70.84Limit Up57.31MShs Float83.33Historical High47.22Limit Down6.83%Amplitude33.05Historical Low0.20Dividend TTM56.10Avg Price7.22KlotAsk0.36%Div YieldTTM100Lot Size5.58KlotBid
R&G PharmaStudies Key Stats
EPS
According to the latest financial report of R&G PharmaStudies, the latest earnings per share (TTM) for the company is 0.88. Investing in companies with strong earnings per share can potentially provide higher returns.
Currency: CNY
Cumulative Quarterly
Loading...
BVPS
Analyzing a company's fundamentals? Check out R&G PharmaStudies's latest financial report to see how much their book value per share (BVPS) is currently at 18.60.
Currency: CNY
Cumulative Quarterly
Loading...
Current Ratio
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of R&G PharmaStudies shows that the company's current ratio is 4.70, indicating healthy liquidity.
Currency: CNY
Cumulative Quarterly
Loading...
Quick Ratio
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of R&G PharmaStudies, the quick ratio is 4.55, indicating that the company can meet its short-term debt obligations.
Currency: CNY
Cumulative Quarterly
Loading...
ROE
Want to learn more about the financial health of R&G PharmaStudies? The latest ROE figure is 4.78%, indicating that the company has stable profitability.
Currency: CNY
Cumulative Quarterly
Loading...
ROA
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of R&G PharmaStudies, the total asset return on investment (ROA) is 3.93%.
Currency: CNY
Cumulative Quarterly
Loading...
Gross Margin
Gross margin can provide insight into a company's pricing strategy and cost structure. Check R&G PharmaStudies's latest financial report to see how their gross margin is doing - currently at 39.19%.
Currency: CNY
Cumulative Quarterly
Loading...
Net Margin
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of R&G PharmaStudies, the net profit margin is 15.29%, which is a good sign for its profitability.
Currency: CNY
Cumulative Quarterly
Loading...
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Analysis
Price Target
No Data
Heat List
CN
Overall
Symbol
Latest Price
% Chg
No Data